Oculis Holding AG announces management participation in future investor conferences throughout September 2025.
Quiver AI Summary
Oculis Holding AG, a biopharmaceutical company specializing in innovative treatments for ophthalmic and neuro-ophthalmic diseases, announced its participation in several investor conferences in September 2025. Key executives, including CEO Riad Sherif, M.D., and CFO Sylvia Cheung, will attend events such as the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, Pareto Securities Healthcare Conference, and the Leerink Partners Biopharma Summit, engaging in presentations and one-on-one meetings with investors. Oculis is advancing a late-stage clinical pipeline that includes candidates for diabetic macular edema, acute optic neuritis, and dry eye disease. For more details, interested parties can visit their website.
Potential Positives
- Oculis is participating in several prominent investor conferences, showcasing the company's commitment to transparency and engagement with the investment community.
- The presence of Oculis’ CEO and CFO at multiple events underlines the company's strategic focus on building relationships with potential investors.
- Oculis is advancing its late-stage clinical pipeline, which includes innovative treatments for conditions with significant unmet medical needs, indicating strong growth potential.
- Investment interest is likely to be bolstered by the company's differentiated product candidates, particularly OCS-01, which aims to be the first non-invasive treatment for diabetic macular edema.
Potential Negatives
- The announcement primarily focuses on upcoming investor conferences, which may suggest the company needs to actively engage with investors to maintain confidence, potentially indicating underlying concerns about investor interest or company performance.
- The press release does not provide any new information or updates about the company’s product pipeline or clinical trial results, which may disappoint investors looking for progress and accountability.
- Participating in multiple conferences without disclosing substantial developments may be perceived as a lack of significant progress or newsworthy achievements, which could negatively impact investor perceptions of the company's momentum.
FAQ
What investor conferences will Oculis participate in September 2025?
Oculis will participate in the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and others.
Who from Oculis will attend the upcoming conferences?
Riad Sherif, M.D., CEO, and Sylvia Cheung, CFO, will represent Oculis at various investor conferences.
What are Oculis' key product candidates?
Oculis' main candidates include OCS-01 for diabetic macular edema, OCS-05 for optic neuritis, and OCS-02 for dry eye disease.
Where can investors find webcast links for the conferences?
Webcast links will be posted on the Oculis website under the Events & Presentation section in Investors & Media.
How can investors schedule one-on-one meetings with Oculis?
Investors should contact their representatives at the sponsoring institutions to request one-on-one meetings during the conferences.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCS Hedge Fund Activity
We have seen 13 institutional investors add shares of $OCS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 50,568 shares (+inf%) to their portfolio in Q2 2025, for an estimated $981,524
- CITADEL ADVISORS LLC removed 22,911 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $435,996
- MARSHALL WACE, LLP added 20,253 shares (+inf%) to their portfolio in Q2 2025, for an estimated $393,110
- POLEN CAPITAL MANAGEMENT LLC added 19,472 shares (+inf%) to their portfolio in Q2 2025, for an estimated $377,951
- BOSUN ASSET MANAGEMENT, LLC added 19,472 shares (+inf%) to their portfolio in Q2 2025, for an estimated $377,951
- ACUTA CAPITAL PARTNERS, LLC removed 18,282 shares (-14.6%) from their portfolio in Q2 2025, for an estimated $354,853
- UBS GROUP AG added 13,550 shares (+12.0%) to their portfolio in Q2 2025, for an estimated $263,005
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCS Analyst Ratings
Wall Street analysts have issued reports on $OCS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/22/2025
- Chardan Capital issued a "Buy" rating on 05/09/2025
- Baird issued a "Outperform" rating on 03/13/2025
To track analyst ratings and price targets for $OCS, check out Quiver Quantitative's $OCS forecast page.
$OCS Price Targets
Multiple analysts have issued price targets for $OCS recently. We have seen 4 analysts offer price targets for $OCS in the last 6 months, with a median target of $34.5.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $36.0 on 08/27/2025
- Yi Chen from HC Wainwright & Co. set a target price of $33.0 on 08/22/2025
- Daniil Gataulin from Chardan Capital set a target price of $33.0 on 05/09/2025
- Colleen Kusy from Baird set a target price of $41.0 on 03/13/2025
Full Release
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in September.
Wells Fargo Healthcare Conference
September 3-5; Boston, U.S.
Riad Sherif, M.D., Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will attend.
H.C. Wainwright 27th Annual Global Investment Conference
September 8-10; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 8
th
at 2:30 pm ET.
Webcast Link:
Register here
Baird Global Healthcare Conference
September 9-10; New York, U.S.
Company update with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 9
th
at 3:45 pm ET.
Webcast Link:
Register here
Pareto Securities 16th Annual Healthcare Conference
September 16; Stockholm, Sweden
Company update with Páll Ragnar Jóhannesson, Chief Business Officer, scheduled for September 16
th
at 9:15 am CET.
Leerink Partners Biopharma Summit
September 17-19; Healdsburg, U.S.
Riad Sherif, M.D., Chief Executive Officer, will attend.
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
[email protected]
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]
